• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Otsuka Recovery Plan Bears Fruit, Official Says

Otsuka Recovery Plan Bears Fruit, Official Says

July 27, 2020

A COVID-19 rapid response plan that helped one pharma company restart all of its paused studies worldwide by mid-July can serve as a model for other drugmakers trying to recover from the pandemic.

Otsuka Pharmaceutical ordered its 800-plus active testing sites around the world to halt new screening activity three weeks into the crisis and rolled out a restart plan about a month later, says Corey Fowler, director of global clinical development for the Japanese drug manufacturer. As a result, testing has resumed at 95 percent of sites.

The company was able to transition from only face-to-face visits at the beginning of March to conducting all visits virtually by April 9. And on May 6, Otsuka began allowing some sites to return to face-to-face visits.

“In parallel, the operations and the management teams started working with our CRO partners on site visit guides that were specific to each protocol’s scheduled assessments,” Fowler said, speaking at a WCG Clinical webinar last week. “These were instructions that would not only align with the FDA guidance (on conducting clinical trials during the pandemic), but we developed them a la carte per scheduled assessment to ensure subjects were safe and that we were able to collect the data in a way that would be allowed.”

Fowler said Otsuka “had to negotiate, essentially assessment by assessment, for some psychiatric assessments to gain alignment.” He added that the company worked with CROs to modify its existing eSource program to differentiate between data collected virtually vs. in-person, an approach in keeping with FDA recommendations that could be replicated industrywide.

The company was able to start recording COVID-19-related protocol deviations in its eSource system within three weeks and developed an electronic system for recording patient-reported outcomes that it was able to implement by the beginning of June.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing